Treatment of Deep Vein Thrombosis (DVT)

Initial Treatment

For acute DVT, parenteral anticoagulation should be initiated immediately upon diagnosis (Grade 1B) 1
LMWH is preferred over unfractionated heparin for initial treatment of DVT due to superior efficacy in reducing mortality and major bleeding risk 2
Outpatient treatment with LMWH is safe and cost-effective for carefully selected patients without significant comorbidities or high bleeding risk 2
For patients with high clinical suspicion of DVT, treatment with parenteral anticoagulants should be initiated while awaiting diagnostic test results (Grade 2C) 3
The American College of Chest Physicians recommends starting oral anticoagulant within 24 hours of initiating LMWH 2

In patients with DVT and no cancer, direct oral anticoagulants are suggested over vitamin K antagonists (VKAs) such as warfarin (Grade 2B) 4
For patients not treated with direct oral anticoagulants, VKA therapy is suggested over LMWH (Grade 2C) 4
In patients with DVT and cancer, LMWH is suggested over VKA therapy (Grade 2B) or direct oral anticoagulants (Grade 2C) 4

For proximal DVT provoked by surgery, treatment for 3 months is recommended (Grade 1B) 4, 5
For proximal DVT provoked by a nonsurgical transient risk factor, treatment for 3 months is recommended (Grade 1B) 4, 5
For unprovoked DVT, treatment for at least 3 months is recommended (Grade 1B) 4, 5
For unprovoked proximal DVT with low or moderate bleeding risk, extended anticoagulation therapy is suggested (Grade 2B) 4, 5
For DVT associated with active cancer, extended anticoagulation therapy is recommended (Grade 1B) 1

Compression stockings are no longer routinely recommended to prevent post-thrombotic syndrome (Grade 2B) 5, 6
For patients with recurrent VTE on non-LMWH anticoagulants, switching to LMWH is suggested (Grade 2C) 6
Inferior vena cava filters are not recommended for patients with DVT who can be treated with anticoagulants (Grade 1B) 5, 6

The American College of Chest Physicians recommends continuing parenteral anticoagulation for at least 5 days AND until INR ≥2.0 for at least 24 hours if transitioning to warfarin in patients with proximal DVT 7, 8
For patients with provoked proximal DVT, the annual recurrence risk is less than 1% after stopping anticoagulation, and treatment should be stopped after exactly 3 months 7, 8
For patients with unprovoked proximal DVT, the American College of Chest Physicians recommends treating for a minimum of 3-6 months initially, then strongly considering indefinite anticoagulation if bleeding risk is low to moderate 7, 8, 9
The annual recurrence risk exceeds 5% after stopping therapy in patients with unprovoked proximal DVT, which justifies indefinite treatment 7, 8

The American College of Chest Physicians recommends against routinely using compression stockings to prevent post-thrombotic syndrome in patients with proximal DVT 10, 11
The American College of Chest Physicians recommends against using inferior vena cava filters in patients who can receive anticoagulation 10, 11
Catheter-directed thrombolysis should be reserved for highly selected patients who place extremely high value on preventing post-thrombotic syndrome, have access to catheter-directed techniques, and accept the increased bleeding risk 10, 11

Aspirin should not be used as an alternative to anticoagulation in patients with proximal DVT, as it is vastly inferior for VTE prevention 10, 11
The need for indefinite anticoagulation should be reassessed periodically (every 6-12 months) to ensure benefits continue to outweigh risks 7, 8